公开(公告)号：US09944688B2

公开(公告)日：2018-04-17

申请号：US14123258

申请日：2012-06-01

申请人： Sung In Lim ,  Myung Hyun Jang ,  Dae Jin Kim ,  Sung Youb Jung ,  Se Chang Kwon

发明人： Sung In Lim ,  Myung Hyun Jang ,  Dae Jin Kim ,  Sung Youb Jung ,  Se Chang Kwon

IPC分类号： A61K47/48 ,  A61K38/28 ,  A61K47/30 ,  A61P3/10 ,  C07K14/62 ,  A61K47/60 ,  A61K47/52 ,  A61K47/69

CPC分类号： C07K14/62 ,  A61K38/28 ,  A61K47/52 ,  A61K47/60 ,  A61K47/6921

摘要： The present invention relates to a non-peptidyl polymer-insulin multimer comprising two or more of a non-peptidyl polymer-insulin conjugate prepared by linking a non-peptidyl polymer and insulin via a covalent bond, in which the conjugates are complexed with cobalt ion to form a multimer, a method and kit for the preparation of the multimer, a pharmaceutical composition for the prevention or treatment of diabetes comprising the multimer as an active ingredient, and a method for preventing or treating diabetes by administering the composition to a subject.

公开(公告)号：US20140107023A1

公开(公告)日：2014-04-17

申请号：US14123258

申请日：2012-06-01

申请人： Sung In Lim ,  Myung Hyun Jang ,  Dae Jin Kim ,  Sung Youb Jung ,  Se Chang Kwon

发明人： Sung In Lim ,  Myung Hyun Jang ,  Dae Jin Kim ,  Sung Youb Jung ,  Se Chang Kwon

IPC分类号： C07K14/62

CPC分类号： C07K14/62 ,  A61K38/28 ,  A61K47/52 ,  A61K47/60 ,  A61K47/6921

摘要： The present invention relates to a non-peptidyl polymer-insulin multimer comprising two or more of a non-peptidyl polymer-insulin conjugate prepared by linking a non-peptidyl polymer and insulin via a covalent bond, in which the conjugates are complexed with cobalt ion to form a multimer, a method and kit for the preparation of the multimer, a pharmaceutical composition for the prevention or treatment of diabetes comprising the multimer as an active ingredient, and a method for preventing or treating diabetes by administering the composition to a subject.

摘要翻译： 本发明涉及一种非肽基聚合物 - 胰岛素多聚体，其包含通过共价键连接非肽基聚合物和胰岛素而制备的两种或多种非肽基聚合物 - 胰岛素结合物，其中缀合物与钴离子络合 以形成多聚体的制备方法和试剂盒，用于预防或治疗糖尿病的药物组合物，其包含多聚体作为活性成分，以及通过向受试者施用该组合物来预防或治疗糖尿病的方法。

公开(公告)号：US09527898B2

公开(公告)日：2016-12-27

申请号：US14124969

申请日：2012-06-07

申请人： Sung Youb Jung ,  Myung Hyun Jang ,  Ling Ai Shen ,  Young Kyung Park ,  Young Jin Park ,  Se Chang Kwon

发明人： Sung Youb Jung ,  Myung Hyun Jang ,  Ling Ai Shen ,  Young Kyung Park ,  Young Jin Park ,  Se Chang Kwon

IPC分类号： A61K38/17 ,  C07K14/705 ,  A61P3/04 ,  C07K14/575 ,  C07K14/605 ,  A61K45/06 ,  A61K38/22 ,  A61K38/00

CPC分类号： C07K14/605 ,  A61K38/00 ,  A61K38/177 ,  A61K38/22 ,  A61K38/26 ,  A61K45/06 ,  C07K14/575 ,  C07K14/705

摘要： The present invention relates to a novel peptide showing more excellent activities on a glucagon like peptide-1 receptor and a glucagon receptor than native oxyntomodulin, and a composition for the prevention or treatment of obesity comprising the peptide as an active ingredient. Unlike native oxyntomodulin, the novel peptide of the present invention reduces food intake, suppresses gastric emptying, and facilitates lipolysis with reduced side-effects, and also shows excellent receptor-activating effects. Thus, it can be widely used in the treatment of obesity with safety and efficacy.

公开(公告)号：US20140128318A1

公开(公告)日：2014-05-08

申请号：US14124969

申请日：2012-06-07

申请人： Sung Youb Jung ,  Myung Hyun Jang ,  Ling Ai Shen ,  Young Kyung Park ,  Young Jin Park ,  Se Chang Kwon

发明人： Sung Youb Jung ,  Myung Hyun Jang ,  Ling Ai Shen ,  Young Kyung Park ,  Young Jin Park ,  Se Chang Kwon

IPC分类号： C07K14/705 ,  A61K45/06 ,  A61K38/17

CPC分类号： C07K14/605 ,  A61K38/00 ,  A61K38/177 ,  A61K38/22 ,  A61K38/26 ,  A61K45/06 ,  C07K14/575 ,  C07K14/705

摘要： The present invention relates to a novel peptide showing more excellent activities on a glucagon like peptide-1 receptor and a glucagon receptor than native oxyntomodulin, and a composition for the prevention or treatment of obesity comprising the peptide as an active ingredient. Unlike native oxyntomodulin, the novel peptide of the present invention reduces food intake, suppresses gastric emptying, and facilitates lipolysis with reduced side-effects, and also shows excellent receptor-activating effects. Thus, it can be widely used in the treatment of obesity with safety and efficacy.

摘要翻译： 本发明涉及一种与天然胃泌酸调节素相比，胰高血糖素样肽-1受体和胰高血糖素受体的活性更优异的新型肽，以及用于预防或治疗包含该肽作为活性成分的肥胖症的组合物。 与本发明的胃泌酸调节蛋白不同，本发明的新型肽减少食物摄入，抑制胃排空，促进脂肪分解，副作用降低，并且还显示出优异的受体激活作用。 因此，可广泛用于治疗肥胖症的安全性和有效性。

公开(公告)号：US09487569B2

公开(公告)日：2016-11-08

申请号：US14124969

申请日：2012-06-07

申请人： Sung Youb Jung ,  Myung Hyun Jang ,  Ling Ai Shen ,  Young Kyung Park ,  Young Jin Park ,  Se Chang Kwon

发明人： Sung Youb Jung ,  Myung Hyun Jang ,  Ling Ai Shen ,  Young Kyung Park ,  Young Jin Park ,  Se Chang Kwon

IPC分类号： A61K38/17 ,  C07K14/705 ,  A61P3/04 ,  C07K14/575 ,  C07K14/605 ,  A61K45/06 ,  A61K38/22 ,  A61K38/00

摘要： The present invention relates to a novel peptide showing more excellent activities on a glucagon like peptide-1 receptor and a glucagon receptor than native oxyntomodulin, and a composition for the prevention or treatment of obesity comprising the peptide as an active ingredient. Unlike native oxyntomodulin, the novel peptide of the present invention reduces food intake, suppresses gastric emptying, and facilitates lipolysis with reduced side-effects, and also shows excellent receptor-activating effects. Thus, it can be widely used in the treatment of obesity with safety and efficacy.

公开(公告)号：US20140212440A1

公开(公告)日：2014-07-31

申请号：US14126914

申请日：2012-06-15

申请人： Sung Youb Jung ,  Dae Jin Kim ,  Sung Hee Park ,  Young Eun Woo ,  In Young Choi ,  Se Chang Kwon

发明人： Sung Youb Jung ,  Dae Jin Kim ,  Sung Hee Park ,  Young Eun Woo ,  In Young Choi ,  Se Chang Kwon

IPC分类号： A61K47/48 ,  A61K38/26

CPC分类号： A61K47/6889 ,  A61K38/00 ,  A61K38/26 ,  A61K45/06 ,  A61K47/60 ,  A61K47/68 ,  A61K47/6801 ,  A61K47/6811 ,  C07K14/575 ,  C07K2319/30

摘要： The present invention relates to a conjugate comprising oxyntomodulin, an immunoglobulin Fc region, and non-peptidyl polymer wherein the conjugate being obtainable by covalently linking oxyntomodulin to immunoglobulin Fc region via non-peptidyl polymer, and a pharmaceutical composition for the prevention or treatment of obesity comprising the conjugates. The conjugate comprising oxyntomodulin and the immunoglobulin Fc of the present invention reduces food intake, suppresses gastric emptying, and facilitates lipolysis without side-effects, unlike native oxyntomodulin, and also shows excellent receptor-activating effects and long-term sustainability, compared to native oxyntomodulin. Thus, it can be widely used in the treatment of obesity with safety and efficacy.

摘要翻译： 本发明涉及包含胃泌酸调节蛋白，免疫球蛋白Fc区和非肽基聚合物的缀合物，其中通过非肽基聚合物共价连接胃泌酸调节蛋白与免疫球蛋白Fc区域可获得的缀合物和用于预防或治疗肥胖症的药物组合物 包括缀合物。 与天然胃泌酸调节蛋白不同，包含胃泌酸调节蛋白和本发明的免疫球蛋白Fc的缀合物减少食物摄入，抑制胃排空，并且促进脂肪分解而不具有副作用，并且与天然胃泌酸调节素相比也显示出优异的受体激活作用和长期可持续性 。 因此，可广泛用于治疗肥胖症的安全性和有效性。

公开(公告)号：US20130122023A1

公开(公告)日：2013-05-16

申请号：US13810999

申请日：2011-07-21

申请人： Young Eun Woo ,  Jong Soo Lee ,  Ling Ai Shen ,  Dae Jin Kim ,  Sung Youb Jung ,  In Young Choi ,  Se Chang Kwon

发明人： Young Eun Woo ,  Jong Soo Lee ,  Ling Ai Shen ,  Dae Jin Kim ,  Sung Youb Jung ,  In Young Choi ,  Se Chang Kwon

IPC分类号： A61K47/48

CPC分类号： A61K47/48415 ,  A61K31/4164 ,  A61K38/26 ,  A61K45/06 ,  A61K47/68 ,  A61K47/6811 ,  A61K47/6883 ,  C07K14/605 ,  A61K2300/00

摘要： Disclosed is a novel long-acting glucagon conjugate in which glucagon or its derivative is covalently linked to a polymer carrier via a non-peptide linker, and a pharmaceutical composition comprising the same as an effective ingredient useful for the prevention and treatment of obesity. Since the long-acting glucagon conjugate of the present invention shows improved in vivo durability and stability, when used in combination with an anti-obesity drug, it is possible to induce synergistic effects on the loss of body weight and decrease in food intake without causing any side-effects such as fluctuation in blood glucose level. Accordingly, the long-acting peptide conjugate of the present invention is very effective for the prevention and treatment of obesity.

摘要翻译： 公开了一种新颖的长效胰高血糖素缀合物，其中胰高血糖素或其衍生物通过非肽接头共价连接到聚合物载体，以及包含其作为有效成分的药物组合物，其用于预防和治疗肥胖症。 由于本发明的长效胰高血糖素缀合物显示出改善的体内耐久性和稳定性，当与抗肥胖药物组合使用时，可以对体重的损失和食物摄取减少引起协同效应，而不引起 任何副作用，如血糖水平波动。 因此，本发明的长效肽结合物对于预防和治疗肥胖症是非常有效的。

公开(公告)号：US20130028867A1

公开(公告)日：2013-01-31

申请号：US13638821

申请日：2011-04-04

申请人： Dae Jin Kim ,  Min Young Kim ,  Jin Sun Kim ,  Sung Hee Hong ,  Sung Youb Jung ,  Se Chang Kwon

发明人： Dae Jin Kim ,  Min Young Kim ,  Jin Sun Kim ,  Sung Hee Hong ,  Sung Youb Jung ,  Se Chang Kwon

IPC分类号： A61K38/21 ,  A61P25/28 ,  A61P37/06 ,  A61P35/00 ,  C07K14/565 ,  A61P31/12

CPC分类号： A61K38/215 ,  A61K47/68 ,  A61K47/6813 ,  A61K47/6835 ,  C07K14/565 ,  C07K19/00 ,  C07K2317/52 ,  C07K2317/732 ,  C07K2317/734 ,  C07K2319/30

摘要： The present invention relates to a long-acting interferon beta formulation having improved in vivo duration and stability, comprising an interferon beta conjugate that is prepared by covalently linking interferon beta with an immunoglobulin Fc region via a non-peptidyl polymer, and a preparation method thereof. The long-acting interferon beta formulation of the present invention maintains in vivo activity of interferon beta at a relatively high level and remarkably increases the serum half-life thereof, thereby being used for various diseases, for which interferon is efficacious.

摘要翻译： 本发明涉及具有改善的体内持续时间和稳定性的长效型干扰素β制剂，其包含通过非肽基聚合物共价连接干扰素β与免疫球蛋白Fc区制备的干扰素β偶联物及其制备方法 。 本发明的长效干扰素β配方维持干扰素β的体内活性在相当高的水平，并显着提高其血清半衰期，从而被用于干扰素有效的各种疾病。

公开(公告)号：US09731031B2

公开(公告)日：2017-08-15

申请号：US14126914

申请日：2012-06-15

申请人： Sung Youb Jung ,  Dae Jin Kim ,  Sung Hee Park ,  Young Eun Woo ,  In Young Choi ,  Se Chang Kwon

发明人： Sung Youb Jung ,  Dae Jin Kim ,  Sung Hee Park ,  Young Eun Woo ,  In Young Choi ,  Se Chang Kwon

IPC分类号： A61K38/26 ,  A61K47/48 ,  C07K14/605 ,  A61P3/04 ,  C07K14/575 ,  A61K45/06 ,  A61K38/00

CPC分类号： A61K47/6889 ,  A61K38/00 ,  A61K38/26 ,  A61K45/06 ,  A61K47/60 ,  A61K47/68 ,  A61K47/6801 ,  A61K47/6811 ,  C07K14/575 ,  C07K2319/30

摘要： The present invention relates to a conjugate comprising oxyntomodulin, an immunoglobulin Fc region, and non-peptidyl polymer wherein the conjugate being obtainable by covalently linking oxyntomodulin to immunoglobulin Fc region via non-peptidyl polymer, and a pharmaceutical composition for the prevention or treatment of obesity comprising the conjugates. The conjugate comprising oxyntomodulin and the immunoglobulin Fc of the present invention reduces food intake, suppresses gastric emptying, and facilitates lipolysis without side-effects, unlike native oxyntomodulin, and also shows excellent receptor-activating effects and long-term sustainability, compared to native oxyntomodulin. Thus, it can be widely used in the treatment of obesity with safety and efficacy.

公开(公告)号：US09072794B2

公开(公告)日：2015-07-07

申请号：US13810999

申请日：2011-07-21

申请人： Young Eun Woo ,  Jong Soo Lee ,  Ling Ai Shen ,  Dae Jin Kim ,  Sung Youb Jung ,  In Young Choi ,  Se Chang Kwon

发明人： Young Eun Woo ,  Jong Soo Lee ,  Ling Ai Shen ,  Dae Jin Kim ,  Sung Youb Jung ,  In Young Choi ,  Se Chang Kwon

IPC分类号： A61K39/385 ,  A61K39/00 ,  A61K38/26 ,  A61K38/00 ,  A61K38/22 ,  A61K47/48 ,  A61K31/4164 ,  A61K45/06 ,  C07K14/605

CPC分类号： A61K47/48415 ,  A61K31/4164 ,  A61K38/26 ,  A61K45/06 ,  A61K47/68 ,  A61K47/6811 ,  A61K47/6883 ,  C07K14/605 ,  A61K2300/00

摘要： Disclosed is a novel long-acting glucagon conjugate in which glucagon or its derivative is covalently linked to a polymer carrier via a non-peptide linker, and a pharmaceutical composition comprising the same as an effective ingredient useful for the prevention and treatment of obesity. Since the long-acting glucagon conjugate of the present invention shows improved in vivo durability and stability, when used in combination with an anti-obesity drug, it is possible to induce synergistic effects on the loss of body weight and decrease in food intake without causing any side-effects such as fluctuation in blood glucose level. Accordingly, the long-acting peptide conjugate of the present invention is very effective for the prevention and treatment of obesity.

摘要翻译： 公开了一种新颖的长效胰高血糖素缀合物，其中胰高血糖素或其衍生物通过非肽接头共价连接到聚合物载体，以及包含其作为有效成分的药物组合物，其用于预防和治疗肥胖症。 由于本发明的长效胰高血糖素缀合物显示出改善的体内耐久性和稳定性，当与抗肥胖药物组合使用时，可以对体重的损失和食物摄取减少引起协同效应，而不引起 任何副作用，如血糖水平波动。 因此，本发明的长效肽结合物对于预防和治疗肥胖症是非常有效的。